8/8/2013

The European Commission granted Bavarian Nordic approval to market the third-generation smallpox vaccine Imvanex. The approval is a first for the Danish vaccine-maker. Imvanex, which is in late-stage development in the U.S., can be used by patients with HIV, atopic dermatitis and others with weakened immune systems.

Related Summaries